Showing results (1-10 of 78) with videos related to
Sort By:
Pageof 8
Journal of the National Comprehensive Cancer Network : JNCCN|September 4, 2020
A Practical Guide for Using Myelofibrosis Prognostic Models in the ClinicJoan How, Gabriela S HobbsBlood|September 29, 2019
Mutant calreticulin in myeloproliferative neoplasmsJoan How, Gabriela S Hobbs, Ann MullallyBlood Cancer Journal|November 6, 2021
Practice patterns and outcomes of direct oral anticoagulant use in myeloproliferative neoplasm patientsJoan How, Charlotte Story, Siyang Ren, et al.Current Hematologic Malignancy Reports|September 3, 2021
Management Issues and Controversies in Low-Risk Patients with Essential Thrombocythemia and Polycythemia VeraJoan How, Gabriela HobbsCancers|July 26, 2020
Use of Interferon Alfa in the Treatment of Myeloproliferative Neoplasms: Perspectives and Review of the LiteratureJoan How, Gabriela HobbsJournal of the National Comprehensive Cancer Network : JNCCN|September 8, 2022
Interferons as the First Choice of Cytoreduction in Essential Thrombocythemia and Polycythemia VeraJoan How, Gabriela HobbsHematology. American Society of Hematology. Education Program|December 7, 2024
Pregnancy: MPN management before, during, and after pregnancyJoan How, Gabriela HobbsSeminars in Hematology|June 29, 2026
Treatment of myeloproliferative neoplasms: Exploring new horizons of who and when to cytoreduce in patients with polycythemia vera and essential thrombocytosisKatherine J Feder, Gabriela S HobbsCurrent Opinion in Hematology|January 31, 2015
Clinical and molecular genetic characterization of myelofibrosisGabriela S Hobbs, Raajit K RampalHematology/Oncology Clinics of North America|July 5, 2017
The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative NeoplasmsGabriela S Hobbs, Sarah Rozelle, Ann MullallyPageof 8